Topical haemoglobin spray for chronic wound therapy

Oxygenating wounds

- Time to heal diabetic foot ulcers 50% shorter than with standard of care[1]
- Twice as many chronic wounds healed at 8–16 weeks compared to standard of care[2]
- More than 70% lower average pain scores at four weeks than with standard of care in chronic wounds[3]
- Less slough during wound management: 99% less slough in chronic wounds after 4 weeks compared to 33% with standard of care[4]
- Treatment costs in diabetic foot ulcers at least 40% lower than with standard of care[5]

*May vary slightly depending on wound size

References: 1.Hunt, SD., Elg, F. Clinical effectiveness of hemoglobin spray (Granulox®) as adjunctive therapy in the treatment of chronic diabetic foot ulcers. November 2016. 2.Hunt, SD., Elg, F. Hemoglobin spray as adjunct therapy in complex wounds: Meta-analysis versus standard care alone in pooled data by wound type across three retrospective cohort controlled evaluations. SAGE Open Medicine, 2018; 6:1-9. 3.Hunt, SD., Elg, F. The clinical effectiveness of haemoglobin spray as adjunctive therapy in the treatment of chronic wounds. Journal of Wound Care, 2017; 26(9):558-568. 4. Hunt, S., Elg F., Percival S. Assessment of clinical effectiveness of haemoglobin spray as adjunctive therapy in the treatment of sloughy wounds. Journal Wound Care. 2018 Apr; 27(4): 210-219. 5. Brüggenjürgen, B., Hunt, SD., Eberlein, T. Wound management in diabetic foot ulcer (DFU) – incremental cost-analysis of treating diabetic neuropathic foot lesions with adjunct hemoglobin contact spray in Germany. Gesundh ökon Qual manag, 2017; 22:1-8.

Granulox®

Mölnlycke®

How to use Granulox®



1. Wound debridement and irrigation. Especially recommended HOCl / NaOCl products (e.g. Granudacyn®).



2. Thin and even application of Granulox from 5-10cm distance. 1 spray for 1 second covers a wound of 2x3cm.

3. Covering the wound with a breathable, non-occlusive wound dressing.

Unique mode of action – Granulox acts like a shuttle for oxygen molecules

Granulox is an innovative medical device for the treatment of chronic wounds, such as venous leg ulcer, arterial leg ulcer, mixed leg ulcer, diabetic foot ulcers, secondary healing of surgical wounds and pressure injuries. Granulox can also be used on sloughy and infected wounds. Granulox provides the wound with oxygen by means of diffusion. The active substance haemoglobin supplies the base of the wound externally with oxygen. The improved oxygen supply to the base of the wound supports wound healing.



1. From the moment Granulox is sprayed, the highly purified haemoglobin starts to bind oxygen from the enviroment and stores it in its molecular structure. Oxygen loaded haemoglobin diffuses through the wound exudate towards the wound bed.



2. Due to the concentration gradient oxygen is released and the haemoglobin molecule is available to bind oxygen again. The reversible oxygen binding property of haemoglobin means each molecule can contribute to multiple cycles of oxygen binding and release.

The application of Granulox can be adjusted to the frequency of changing the corresponding wound dressing. Apply Granulox every time the dressing is changed, but at least every 3 days.

Ordering information*

Product Code	Size	Treatments per can
360001	12ml	30

*Depending on the size of the wound. One spray of 1-2 seconds is normally sufficient to cover a wound area of 2 x 3cm.

Wound healing (wound size reduction)[1]



4 weeks of treatment[1]:

63% wound size reduction in Granulox group with 5 patients fully healed

26% wound size reduction in Standad Care group with 1 patient fully healed

Wound size reduction in patients with diabetic foot ulceration receiving Standard of Care + Granulox compared to retrospective control cohort with SoC alone (20/20 patients)[1].

www.molnlycke.co.nz

Mölnlycke®